-
Mashup Score: 1Patient Characteristics to Consider for Doublet, Triplet Therapy in mHSPC and mCRPC | GU Oncology Now - 10 hour(s) ago
In the second part of this roundtable series, the panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
Source: guoncologynow.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Treatment With Investigational TAR-200 Demonstrates Promising Results With BCG-Unresponsive HR NMIBC | GU Oncology Now - 2 day(s) ago
TAR-200 monotherapy is well tolerated and shows promising efficacy in treating HR NMIBC, according to data from SunRISe-1.
Source: guoncologynow.comCategories: General Medicine News, UrologyTweet-
❇️ At #SUO24, Dr. @siadaneshmand presented results on the safety and tolerability of monotherapy with the investigational agent TAR-200 in a cohort from the ongoing phase 2B SunRISe-1 trial. 🔎 Learn more about the results seen for BCG-unresponsive NMIBC: https://t.co/9zANdPJXbz
-
-
Mashup Score: 3Urology on the Beach 2025 Preview: New Trends in RCC Care and Imaging | GU Oncology Now - 3 day(s) ago
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Source: guoncologynow.comCategories: General Medicine News, Onc News and JournalsTweet-
☀️ Dr. Brian Shuch @KidneyCancerDoc previews his upcoming sessions at Urology on the Beach 2025. 📺 His presentation will cover the use of molecular imaging agents and their role in risk stratification and informed treatment decisions: https://t.co/zzvHD6fjcu @dsui_miami_uro
-
-
Mashup Score: 0Biomarkers and Imaging in Upfront Metastatic Prostate Cancer Diagnosis | GU Oncology Now - 5 day(s) ago
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Dive in to our new roundtable on the mHSPC and mCRPC treatment landscape, featuring @DavidMorrismd moderating a panel including Drs. John Phillips and Jeremy McDuffie of @TNOncology, @katy_beckermann, and @alantanmd. 👉 Watch part one now: https://t.co/3XtXtGv2Uo https://t.co/aG2cQvwMFi
-
-
Mashup Score: 1Inverse Correlation Between PSMA and Risk of Metastatic Progression of RCC Post Surgery | GU Oncology Now - 6 day(s) ago
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔎 In a study presented at #SUO24, greater expression of PSMA in patients with non-metastatic #ccRCC was found to be linked to enhanced PFS, highlighting its potential role as a prognostic marker: https://t.co/eXD7EP5aV5
-
-
Mashup Score: 030-Day Postoperative Complication Risk Higher in Radical Prostatectomy With Pelvic Lymph Node Dissec | GU Oncology Now - 7 day(s) ago
Radical prostatectomy with pelvic lymph node dissection increases risks of complications like DVT and lymphatic leaks.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🚩 Patients with #prostatecancer who undergo radical prostatectomy with PLND may be at an increased risk of 30-day postoperative complications than those who received the surgery without PLND. 👉 Learn more about the results of a recent cohort study: https://t.co/prALXaGGcE
-
-
Mashup Score: 5
Drs. Saji and Lebastchi provide an in-depth overview of focal therapy for prostate cancer, including HIFU and IRE therapies.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 At the AUA Western Section meeting in Hawaii, GU Oncology Now section editor Dr. Akhil Saji and @AmirLebastchi discuss the advancements and applications of focal therapy for #prostatecancer, exploring current standards and ideal patient selection: https://t.co/Oo4JGj6e8y
-
-
Mashup Score: 1Decipher Genomic Classifier Augments Progression Surveillance for Patients With Prostate Cancer | GU Oncology Now - 9 day(s) ago
Standard risk assessment plus genomic classification at the initiation of active surveillance for prostate cancer helps predict disease progression.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔬 Data presented by Mark Sultan of @MountSinaiNYC at #SUO24 shows that the addition of a novel genomic classifier during active surveillance for #prostatecancer was shown to predict disease progression independently from clinical risk assessment tools: https://t.co/uJe2xY7UIQ
-
-
Mashup Score: 0Survival Rates in High-Risk Non-Clear Cell RCC Comparable to Clear Cell RCC With Adjuvant Pembrolizu | GU Oncology Now - 12 day(s) ago
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔬 A recent study has revealed that patients with HR #nccRCC exhibit comparable 5-year cancer-specific and OS outcomes compared with #ccRCC. 👉 These new findings highlight that patients with nccRCC may benefit from adjuvant therapy: https://t.co/eCCAh8Jqwo
-
-
Mashup Score: 0Treating BCG-Refractory Disease and Explaining NMIBC Treatment Options to Patients | GU Oncology Now - 13 day(s) ago
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
Source: guoncologynow.comCategories: General Medicine News, Oncologists1Tweet-
📺 In the second part of our NMIBC roundtable, the panelists address the increasing availability of intravesical and systemic therapies, the importance of accurate risk stratification, and the role of education for both health care providers and patients: https://t.co/chU75Qvzm6
-
📺 Part 2 of our roundtable featuring Drs. @DavidMorrismd, John Phillips and Jeremy McDuffie of @TNOncology, @katy_beckermann, and @alantanmd focuses on key considerations for patient selection in doublet and triplet therapies for mHSPC & CRPC. Watch now: https://t.co/RR824sCmzX